Medicine Matters oncology

After progression on enfortumab, our options include erdafitinib, let's not forget. It's a orally administered small molecule inhibitor against VEGFR. And it is approved for patients with selected FGFR2 and FGFR3 mutations, which represent about 15% to 20% of all patients with advanced disease. So that's an effective option that we should reach for for patients that are biomarker-positive.

And then obviously, importantly, in that third line and beyond setting after enfortumab, clinical trials will then become the preferred option. There are a number of studies looking at novel immune targets, other ADCs, sacituzumab govitecan, is currently still being-- is still in development. There's the tropics study that is currently evaluating that as well. So there are trials of novel agents and other immunotherapies, but I would generally counsel patients toward clinical trial options.